Q3 FY2026
Filed Nov 12, 2026AIR Global Q3 2026 revenue rose 11.1% to $99.8 million and Adjusted EBITDA rose 7.7% to $30.9 million, while the nine-month result was a net loss of $(74.2) million after listing-related charges
Q3 2026 showed the strongest top-line growth in the filing (revenue +11.1%, FSM shipment volumes +5.8%) and Adjusted EBITDA grew 7.7%. Offsetting this, gross margin and Adjusted EBITDA margin fell, nine-month results were a net loss driven by one-time items, Europe and New Growth Categories remain weak, and year-end leverage guidance was raised to approximately 2.5x from approximately 2.1x.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, Q3 2026other | $99.8M | – | 11.1% |
| Revenue, 9M 2026other | $306.7M | – | 6.0% |
| Gross profit, Q3 2026other | $53.2M | – | 9.8% |
| Gross profit, 9M 2026other | $170M | – | 4.6% |
| Cost of sales, Q3 2026other | $46.6M | – | 12.7% |
| Cost of sales, 9M 2026other | −$136.7M | – | – |
| Gross margin, Q3 2026other | 53.3% | – | – |
| Gross margin, 9M 2026other | 55.4% | – | – |
| Distribution expenses, 9M 2026other | −$34.05M | – | – |
| General and administrative expenses, 9M 2026other | −$91.66M | – | – |
| Provision for expected credit losses on trade receivables, 9M 2026other | −$1.11M | – | – |
| Other operating (losses) / gains, 9M 2026other | −$88.86M | – | – |
| Operating profit, Q3 2026other | $17.9M | – | 5.1% |
| Operating (loss), 9M 2026other | −$45.7M | – | NM |
| Profit before taxation, Q3 2026other | $8.1M | – | decreased 1.3% |
| Fair value loss on financial instruments, Q3 2026other | $2.5M | – | – |
| Finance costs, Q3 2026other | $7.2M | – | – |
| Taxation, Q3 2026other | $400K | – | – |
| Profit for the period, Q3 2026other | $7.6M | – | 13.8% |
| (Loss) for the period, 9M 2026other | −$74.2M | – | NM |
| Basic EPS, Q3 2026other | $0.052 | – | 10.6% |
| Basic (loss) per share, 9M 2026other | $(0.509) | – | NM |
| Diluted (loss) per share, 9M 2026other | $(0.509) | – | – |
| EBITDA, Q3 2026non-GAAP | $23.7M | – | 9.0% |
| EBITDA, 9M 2026non-GAAP | −$28.4M | – | NM |
| Adjusted EBITDA, Q3 2026non-GAAP | $30.9M | – | 7.7% |
| Adjusted EBITDA, 9M 2026non-GAAP | $102.7M | – | 2.3% |
| Adjusted EBITDA margin, Q3 2026non-GAAP | 31.0% | – | – |
| Adjusted EBITDA margin, 9M 2026non-GAAP | 33.5% | – | – |
| FSM shipment volume change, Q3 2026other | 5.8% | – | – |
| Price/mix change, Q3 2026other | 5.0% | – | – |
| FSM shipment volume change, 9M 2026other | (4.6)% | – | – |
| Price/mix change, 9M 2026other | 11.1% | – | – |
| Revenue, FSM Americas, Q3 2026other | $21.9M | – | 25.6% |
| Revenue, FSM MEAA, Q3 2026other | $64.1M | – | 9.4% |
| Revenue, FSM Europe, Q3 2026other | $13.8M | – | 4.9% |
| Revenue, New Growth Categories, Q3 2026other | −$100K | – | NM |
| Revenue, FSM Americas, 9M 2026other | $64.8M | – | 10.0% |
| Revenue, FSM MEAA, 9M 2026other | $200.8M | – | 5.7% |
| Revenue, FSM Europe, 9M 2026other | $39.1M | – | 2.1% |
| Revenue, New Growth Categories, 9M 2026other | $2.1M | – | (2.6)% |
| Adjusted EBITDA, FSM Americas, Q3 2026non-GAAP | $7.8M | – | (3.6)% |
| Adjusted EBITDA, FSM MEAA, Q3 2026non-GAAP | $25.1M | – | 2.4% |
| Adjusted EBITDA, FSM Europe, Q3 2026non-GAAP | $900K | – | NM |
| Adjusted EBITDA, New Growth Categories, Q3 2026non-GAAP | −$2.9M | – | NM |
| Adjusted EBITDA, FSM Americas, 9M 2026non-GAAP | $27.5M | – | 10.5% |
| Adjusted EBITDA, FSM MEAA, 9M 2026non-GAAP | $84.9M | – | (2.2)% |
| Adjusted EBITDA, FSM Europe, 9M 2026non-GAAP | $1.1M | – | (41.7)% |
| Adjusted EBITDA, New Growth Categories, 9M 2026non-GAAP | −$10.8M | – | NM |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| FSM - Americas, Q3 2026Company states revenue was driven by 28.5% volume growth and negative 2.3% price/mix, driven by timing of trade incentives. Adjusted EBITDA decreased 3.6% to $7.8 million, mainly reflecting higher cost of goods sold. | $21.9M | – | 25.6% |
| FSM - MEAA, Q3 2026Company states revenue was driven by 3.0% volume growth and 6.2% positive price/mix. Adjusted EBITDA increased 2.4% to $25.1 million, dampened by higher ongoing central office costs associated with being a public company and higher cost of goods sold. | $64.1M | – | 9.4% |
| FSM - Europe, Q3 2026Company states revenue was driven by 6.9% volume growth and negative 1.8% price/mix. Adjusted EBITDA was $0.9 million, compared with breakeven in the prior-year period. Company states Europe remained challenging, as excise tax increases and a lack of enforcement continue to drive illicit products. | $13.8M | – | 4.9% |
| New Growth Categories, Q3 2026Company states revenue was negative $0.1 million, reflecting timing of trade incentives, compared with positive $0.6 million in Q3 2025. Adjusted EBITDA loss narrowed to $2.9 million from $3.9 million, which the company says reflects lower operating costs and more focused investment behind new product launches. | −$100K | – | NM |
| FSM - Americas, 9M 2026Company states revenue was driven by 7.4% volume growth and 2.4% price/mix. Adjusted EBITDA increased 10.5% to $27.5 million. | $64.8M | – | 10.0% |
| FSM - MEAA, 9M 2026Company states price/mix of 13.5% offset a 6.9% volume decline. Adjusted EBITDA decreased 2.2% to $84.9 million. | $200.8M | – | 5.7% |
| FSM - Europe, 9M 2026Company states revenue was driven by 11.3% volume growth and negative 8.2% price/mix. Adjusted EBITDA decreased to $1.1 million from $1.8 million. | $39.1M | – | 2.1% |
| New Growth Categories, 9M 2026Company states revenue decreased 2.6% to $2.1 million. Adjusted EBITDA loss narrowed to $10.8 million from $13.2 million in the prior-year period. | $2.1M | – | (2.6)% |
FY2026 (reiterated), with FY2027 and medium-term items outlook
- RevenueGrowth of 4% to 6% in U.S. dollars
- Tax rateApproximately 15%
- NoteShipment volumes broadly stable compared with FY2025, including an approximately 1.5% headwind from weaker Global Travel Retail volumes resulting from the Middle East conflict
- NoteAdjusted EBITDA growth of low- to mid-single digits, partly offset by incremental public-company costs, the accelerated reorganization of the factory footprint, and higher logistics and raw-material costs
- NoteYear-end Net Debt to Adjusted EBITDA of approximately 2.5x, compared with the prior expectation of approximately 2.1x, primarily reflecting bond-issuance cashflows and the timing of working-capital movements; working-capital effects expected to normalize during 2027
- NoteCapital expenditures of $11 million to $14 million, compared with $15 million to $18 million previously
- NoteFY2027 and medium-term: low-single-digit organic FSM shipment-volume growth; mid-single-digit FSM revenue growth in U.S. dollars; high-single-digit FSM Adjusted EBITDA growth in U.S. dollars
- NoteNet Debt to Adjusted EBITDA at or below 2.0x by December 2027, including the impact of dividends and share repurchases
- NoteTiming and scale of New Growth Categories revenue and Adjusted EBITDA contributions depend on FDA acceptance of PMTA applications
Capital returns
- Company intends to commence an annual dividend of $0.28 per share, paid in quarterly installments, starting Q1'27, with Q1'27 results expected to be announced in May 2027; thereafter a progressive dividend policy
- Company intends to undertake up to $100 million of share repurchases through December 2029, subject to market conditions, capital requirements and applicable regulatory approvals
- Company states capital returns are expected to be funded from equity free cash flow, defined as cash flow from operations less capital expenditure, interest expense, and principal and interest payments on lease liabilities
- Dividends and repurchases remain subject to Board approval, available distributable reserves, any required shareholder authority, and other conditions stated in the release
What drove it
- Company states Q3 2026 revenue growth reflected 5.8% volume growth and 5.0% price/mix, with minimal FX impact as AIR operates largely in U.S. dollars or U.S. dollar-pegged currencies
- Company states shipment activity continued to recover after the Strait of Hormuz disruption in H1 2026, with alternative routes coming into operation
- Company states nine-month Adjusted EBITDA growth was supported by underlying business performance, while public-company costs, factory reorganization, and higher logistics and raw-material costs were cited as offsets in its full-year outlook
- Company states the Greentank investment of $20 million at a pre-money valuation of $170 million, announced July 29, 2026, provides commercial advantages and supports the planned U.S. launch of Crown Switch; an option to increase ownership by a further 20% over 24 months at a $250 million valuation is also included
- Company states it submitted a PMTA for Crown Switch and that AIR is on track to open its Romania factory during Q1'27
Concerns
- Nine-month net loss of $(74.2) million. Company lists one-time items including $48.2 million of non-cash listing expense under IFRS 2, $47.7 million of IPO-related cash costs, $14.1 million of non-cash share-based compensation, $10.5 million of public company readiness costs, $4.3 million of supply chain costs from the Strait of Hormuz disruption, $3.4 million of regulatory costs for the PMTA, and $2.2 million of provisions, write-offs and associated legal costs
- Q3 2026 gross margin of 53.3% compared with 54.0% in Q3 2025; company states cost of sales increased 12.7% reflecting higher logistics, material and factory footprint costs. Nine-month gross margin of 55.4% compared with 56.2%
- Adjusted EBITDA margin of 31.0% in Q3 2026 compared with 31.9% in Q3 2025, and 33.5% for 9M 2026 compared with 34.7%
- Year-end 2026 leverage guidance of approximately 2.5x, compared with the prior expectation of approximately 2.1x
- Europe Adjusted EBITDA of $1.1 million for 9M 2026, down 41.7%; company states Europe remains challenging due to excise tax increases, lack of enforcement and illicit products
- MEAA 9M 2026 volume declined 6.9% and MEAA Adjusted EBITDA declined 2.2%
- New Growth Categories revenue was negative $(0.1) million in Q3 2026; company attributes this to timing of trade incentives
- Company states that future decisions to defer, reduce or discontinue investment in certain workstreams may represent indicators of impairment and could result in impairment losses and write-offs; the capital expenditure range was lowered to $11 million to $14 million from $15 million to $18 million
- Forward-looking statements list previously identified material weaknesses in internal control over financial reporting as a risk factor
What to watch
- Whether FSM volume recovery continues in Q4 2026 against the full-year outlook of broadly stable volumes versus FY2025
- Adjusted EBITDA delivery against low- to mid-single-digit growth guidance, given higher logistics, raw-material and public-company costs
- Year-end 2026 Net Debt to Adjusted EBITDA of approximately 2.5x and the expected 2027 normalization of working capital
- FDA review of the Crown Switch PMTA and the timing of New Growth Categories contributions
- Opening of the Romania factory in Q1'27
- First annual dividend of $0.28 per share in quarterly installments, with Q1'27 results expected in May 2027
- Execution of up to $100 million of share repurchases through December 2029
- Progress toward leverage at or below 2.0x by December 2027
- Europe and New Growth Categories profitability and any impairment or write-off indicators
Balance sheet and cash flow
- Cash and cash equivalents of $38,944 thousand at 30 September 2026, compared with $119,456 thousand at 31 December 2025
- Total assets of $728,929 thousand at 30 September 2026, compared with $723,190 thousand at 31 December 2025
- Net assets of $197,608 thousand at 30 September 2026, compared with $209,370 thousand at 31 December 2025
- Restricted deposit of $18,200 thousand at 30 September 2026 (none shown at 31 December 2025)
- Trade and other receivables of $130,591 thousand at 30 September 2026, compared with $93,160 thousand at 31 December 2025; inventories of $73,020 thousand, compared with $55,331 thousand
- Total borrowings including lease liabilities of $403.7 million, cash and cash equivalents of $38.9 million, Net Debt of $364.8 million (non-IFRS), rolling 12-month Adjusted EBITDA of $141.6 million (non-IFRS), and Net Debt / Adjusted EBITDA of 2.6x (non-IFRS), as at 30 September 2026
- Senior unsecured notes of $425 million with a 7.875% coupon maturing in 2031, priced in September 2026 and closed on October 1, 2026; proceeds used to fully refinance the existing term loan facility and repay the outstanding revolving credit facility
- No cash flow statement or operating or free cash flow figure is included in the release; equity free cash flow is defined but not quantified
Analysis
AIR Global reported Q3 2026 revenue of $99.8 million, up 11.1% from $89.8 million, with company-stated shipment volumes up 5.8% and price/mix up 5.0%. The company links the quarter to a recovery in shipment activity after the Strait of Hormuz disruption in the first half. Gross profit rose 9.8% to $53.2 million, but gross margin was 53.3% against 54.0% a year earlier, and the company states cost of sales rose 12.7% on higher logistics, material and factory footprint costs. Adjusted EBITDA grew 7.7% to $30.9 million, with the margin at 31.0% against 31.9%. Operating profit was $17.9 million compared with $17.0 million, and Q3 profit for the period was $7.6 million compared with $6.7 million, helped by finance costs of $7.2 million against $8.7 million, although the filing also records a $2.5 million fair value loss and profit before taxation fell 1.3% to $8.1 million.
The nine-month picture is weaker. Revenue rose 6.0% to $306.7 million, but FSM shipment volumes declined 4.6%, with the company attributing price/mix of 11.1% to offsetting that decline. Gross margin fell to 55.4% from 56.2%. The 9M loss from operations of $(45.7) million and net loss of $(74.2) million reflect a long list of one-time items, most notably $48.2 million of non-cash IFRS 2 listing expense and $47.7 million of IPO-related cash costs. Basic loss per share was $(0.509) against earnings of $0.270. Adjusted EBITDA for the nine months rose 2.3% to $102.7 million, with the margin at 33.5% against 34.7%. Segment results diverge: FSM Americas grew revenue 10.0% and Adjusted EBITDA 10.5% for 9M, while FSM MEAA Adjusted EBITDA declined 2.2% and FSM Europe Adjusted EBITDA declined 41.7%. Q3 Americas revenue rose 25.6%, which the company attributes to 28.5% volume growth with price/mix negative on timing of trade incentives.
Capital allocation changed in several directions at once. The company issued $425 million of 7.875% senior unsecured notes due 2031, closed October 1, 2026, and used the proceeds to refinance the term loan and repay the revolver. It intends to start a $0.28 per share annual dividend, paid quarterly from Q1'27, and up to $100 million of buybacks through December 2029. Year-end 2026 leverage guidance was raised to approximately 2.5x from approximately 2.1x, which the company attributes to bond-issuance cashflows and working-capital timing. Cash fell to $38,944 thousand from $119,456 thousand at 31 December 2025, and reported Net Debt / Adjusted EBITDA stood at 2.6x on a non-IFRS basis. Capital expenditure guidance was lowered to $11 million to $14 million, and the company warns that deferring or discontinuing investment may signal impairment. The cash flow statement is not included, so operating and free cash flow cannot be read from the filing.
The guidance was reiterated for FY2026 (revenue growth of 4% to 6% in U.S. dollars and low- to mid-single-digit Adjusted EBITDA growth), with a roughly 15% tax rate and roughly 1.5% GTR volume headwind. The FY2027 and medium-term framework calls for low-single-digit organic FSM volume growth, mid-single-digit FSM revenue growth and high-single-digit FSM Adjusted EBITDA growth, with leverage at or below 2.0x by December 2027, contingent on FDA acceptance of the PMTA filings for New Growth Categories. The key items to track are whether the Q3 volume recovery holds, whether gross and Adjusted EBITDA margins stabilize, the execution of the leverage path, and the timing of FDA review.
Management, verbatim
Third-quarter revenue increased 11.1% as volumes grew 5.8% and shipment activity continued to recover from the supply-chain disruptions experienced in the first half of the year.
Stuart Brazier, Chief Executive Officer
Logistics and material costs remain elevated as a consequence of the geopolitical situation; however, end-consumer demand remains resilient and performance across our key markets was strong, giving us confidence to reiterate our 2026 revenue growth guidance (in U.S. dollars) of 4%–6% and Adjusted EBITDA guidance of low- to mid-single-digit growth.
Stuart Brazier, Chief Executive Officer
Through equity free cash flow generation and with continued growth in Adjusted EBITDA, we expect leverage to decline over time and to be at or below 2.0x by December 2027.
Bassem Lotfy, Chief Financial Officer
Not in the filing
stated, not guessed- Q3 2025 cost of sales in dollars is not printed; only the 12.7% increase is stated
- Q3 2025 profit before taxation in dollars is not printed; only the 1.3% decrease is stated
- Change in Q3 gross margin in basis points is not printed
- Q3 2026 diluted EPS is not printed
- Sequential (prior quarter, Q2 2026) comparisons are not printed
- Cash flow statement, operating cash flow, capital expenditure actuals and free cash flow are not included in the release
- Prior-period Net Debt and Net Debt / Adjusted EBITDA values are not printed, other than the approximately 2.1x prior year-end expectation
- Total borrowings at 31 December 2025 are not printed as a single figure
- Q3 2025 operating expense detail beyond the nine-month lines is not printed
- Share price reaction, consensus estimates and analyst expectations are not in the documents
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.